Versatile lyophilizer for research, development or small-scale production
Allows for easy and intuitive scale-up from research.
The Genesis lyophilizer from SP Scientific has been designed with versatility in mind so that this freeze dryer can meet virtually any research, development or small-scale production lyophilization application.
The Genesis is highly configurable and designed to deliver shelf temperatures as low as -70 °C, condenser temperatures to -85 °C, operate in bulk or stoppering configurations. Suitable applications include; pharmaceutical development, tissue processing and banking, natural products research and diagnostics reagent production.
Allowing for easy and intuitive scale-up from research, the Genesis makes the perfect mid-scale lyophilizer. The compact, free-standing, mobile design enables the system to be optimally configured to almost any application. Ergonomic profiling allows easy inspection of the vacuum pump and facilitates quick and trouble-free oil changes. For applications where a sterile environment is critical, an easy-to-install clean room version of the Genesis lyophilizer is also available.
The product chamber, shelves and condenser chamber are made of durable 316L stainless steel, with a squared product chamber that ensures easy cleaning and maximum shelf area. A 4-inch diameter port increases vapour flow from the product to the condenser chamber maximising system productivity. Reliable refrigeration systems with proven CFC-free refrigerants allow Genesis Lyophilizers to achieve a wide range of temperatures enabling freeze drying of all sample types.
The Genesis has a range of powerful control options which allow every aspect of the freeze-drying process to be monitored and controlled. Multiple stage freezing and drying steps can be programmed to enable the best results to be obtained from any product. Controls range from the simple Wizard microprocessor control system to a fully 21 CFR part 11 compliant PC-based control system.
The Genesis is available with up to six bulk drying shelves and five vial processing shelves. An expanded range of shelf arrangements, available with a shelf latching kit, allows you to configure it to process a wide variety of vial sizes, with stoppering an option.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.